Sector News

Eisai Enters Agreement to Transfer North Carolina Plant to Biogen

July 20, 2015
Life sciences
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a definitive agreement to transfer ownership of its Research Triangle Park-based manufacturing facility (North Carolina Plant) in North Carolina, the United States, to Biogen Inc.
 
This agreement expands upon the strategic manufacturing alliance agreement concerning the North Carolina Plant entered into in December 2012. Under the new agreement, Eisai will transfer to Biogen the entire North Carolina Plant site, including the oral solid dose (OSD) facility which had been leased by Biogen. Additionally, Biogen will continue to manufacture OSD products for Eisai, and Eisai will subsequently commission Biogen to manufacture all Eisai parenteral products currently made at the parenteral facility. In accordance with the execution of this agreement, approximately 100 Eisai Inc. employees may be offered employment at Biogen, effective upon closing of the deal. This agreement is expected to close in the second quarter, subject to the satisfaction of all customary provisions generally attached to similar transactions.
 
This decision is based on Eisai’s global logistics strategy which aims to optimize the global supply chain. After the transfer of manufacturing operations to Biogen takes place, Eisai will continue to base supply chain management services in the Research Triangle Park area. Together with maintaining operations of global contract manufacturing management and quality assurance in North Carolina, production at the Baltimore plant in Maryland will continue unchanged to supply products for the United States as well as the global market.
 
By responding flexibly to the changes in the global environment and the diversification of customer needs as well as realizing the stable supply of high quality products at affordable pricing, Eisai strives to address the diverse needs of, and further contribute to increasing the benefits for, patients and their families.
 
Source: Eisai

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”